US 12,077,485 B2
Lipid nanoparticle compositions for delivering circular polynucleotides
Allen T. Horhota, Cambridge, MA (US); Junghoon Yang, Cambridge, MA (US); Kevin J. Kauffman, Newton, MA (US); Thomas Barnes, Cambridge, MA (US); Robert Alexander Wesselhoeft, Cambridge, MA (US); Amy M. Becker, Cambridge, MA (US); and Gregory Motz, Cambridge, MA (US)
Assigned to Orna Therapeutics, Inc., Watertown, MA (US)
Filed by Orna Therapeutics, Inc., Watertown, MA (US)
Filed on Nov. 3, 2023, as Appl. No. 18/501,958.
Application 18/501,958 is a continuation of application No. PCT/US2022/049313, filed on Nov. 8, 2022.
Claims priority of provisional application 63/277,055, filed on Nov. 8, 2021.
Prior Publication US 2024/0158336 A1, May 16, 2024
Int. Cl. C07C 229/24 (2006.01); A61K 9/127 (2006.01); A61K 31/7105 (2006.01)
CPC C07C 229/24 (2013.01) [A61K 9/1272 (2013.01); A61K 31/7105 (2013.01)] 28 Claims
OG exemplary drawing
 
1. An ionizable lipid represented by Formula (13*):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
n* is an integer from 2 to 7;
Ra is hydrogen;
Rb is hydrogen or C1-C6 alkyl;
R1 and R2 are each independently —(CH2)qC(O)O(CH2)rCH(R8)(R9),
wherein:
q is an integer from 0 to 12,
r is 0,
R8 is H or R10, wherein one R8 is hydrogen, and
R9 and R10 are independently unsubstituted linear C1-C12 alkyl or unsubstituted linear C2-C12 alkenyl.